{"nctId":"NCT04712903","briefTitle":"Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer","startDateStruct":{"date":"2020-12-16","type":"ACTUAL"},"conditions":["Small Cell Lung Carcinoma Extensive Disease"],"count":101,"armGroups":[{"label":"Durvalumab in Combination with Platinum-Etoposide","type":"EXPERIMENTAL","interventionNames":["Drug: Durvalumab","Drug: Cisplatin","Drug: Etoposide","Drug: Carboplatin"]}],"interventions":[{"name":"Durvalumab","otherNames":[]},{"name":"Cisplatin","otherNames":[]},{"name":"Etoposide","otherNames":[]},{"name":"Carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically documented Small cell Lung Cancer with extensive disease.\n* Patients who had received chemoradiotherapy for LS-SCLC and have experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle, can be included under investigator criteria.\n* Brain metastases; must be asymptomatic or have been treated at least 2 weeks prior to study treatment and are currently receiving 10 mg/day or less of prednisone or equivalent.\n* Patients must be considered suitable to receive a platinum-based chemotherapy regimen as 1st line treatment for ES-SCLC.\n* ECOG Performance Status of 0-2 at enrolment.\n* No prior exposure to immune-mediated therapy for cancer.\n* Adequate hematologic and organ function.\n* Life expectancy of at least 12 weeks.\n* Body weight \\>30 kg.\n\nExclusion Criteria:\n\n* Any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest).\n* Paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of PNS\n* Active infection including tuberculosis, HIV, hepatitis B anc C\n* Active or prior documented autoimmune or inflammatory disorders\n* Uncontrolled intercurrent illness, including but not limited to interstitial lung disease.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Adverse Events (AEs) Grade ≥ 3","description":"Patients with AEs grade ≥ 3 acording to NCI CTCAE v5.0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients With Immune-mediated Adverse Events (imAE)","description":"Patients with immune-mediated adverse events (imAE) per patient","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS).","description":"PFS: Defined as the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from investigational product or receives another anticancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable assessment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Objetive Response Rate (ORR)","description":"Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) Criteria for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR: Defined as the time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Discontinuation (TTD)","description":"TTD: Defined as the time from the first date of treatment until the end of treatment date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overal Survival (OS)","description":"OS: Defined as the time from the first date of treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS Rate at 6 Months","description":"Percentage of participants remaining alive without disease progression at 6 months after initiation of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null}]}]}]},{"type":"SECONDARY","title":"PFS Rate at 12 Months","description":"Percentage of participants remaining alive without disease progression at 12 months after initiation of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null}]}]}]},{"type":"SECONDARY","title":"DoR Rate at 12 Months","description":"Percentage of responders remaining alive without disease progression at 12 months after first response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Rate at 6 Months","description":"Percentage of participants remaining alive at 6 months after initiation of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Rate at 12 Months","description":"Percentage of participants remaining alive at 12 months after initiation of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null}]}]}]},{"type":"SECONDARY","title":"OS Rate at 18 Months","description":"Percentage of participants remaining alive at 18 months after initiation of study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Global Health Status Domain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"30.8"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Physical Functioning Domain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":"29.4"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Role Functioning Domain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.0","spread":"36.0"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Emotional Functioning Domain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"30.4"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Cognitive Functioning Domain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":"24.0"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Social Functioning Domain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor each of these scales, scores range from 0 to 100. For the Global Health Status and the 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.0","spread":"31.0"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Fatigue, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","spread":"29.4"}]}]}]},{"type":"SECONDARY","title":". EORTC QLQ-C30: Pain, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"29.2"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Nausea and Vomiting, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"20.1"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Dyspnoea, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"37.2"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Insomnia, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"36.4"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Appetite Loss, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"36.3"}]}]}]},{"type":"SECONDARY","title":"EORCT QLQ-C30: Constipation, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"33.5"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Diarrhoea, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"18.1"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-C30: Financial Difficulties, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-C30 was administered on day 1 and on the final visit (last treatment visit). EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical Functioning, Role Functioning, Cognitive Functioning, Emotional Functioning, Social Functioning), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrohea, Financial difficulties).\n\nFor the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"22.0"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Coughing, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"29.7"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Haemoptysis, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"15.2"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Dyspnoea, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"24.1"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Pain in Arm or Shoulder, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"33.4"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Pain in Other Parts, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"39.4"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Sore Mouth, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"13.0"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Peripheral Neuropathy, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"27.4"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Alopecia, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"37.5"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Dysphagia, Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"23.6"}]}]}]},{"type":"SECONDARY","title":"EORTC QLQ-LC13: Chest Pain Item Change From Baseline to End of Treatment Visit","description":"EORTC QLQ-LC13 is a 13-items questionnaire used in clinical research to assess health-related quality of life in lung cancer patients. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (Coughing, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.\n\nScores are calculated and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms.\n\nChange from baseline is the difference in the score between the end of treatment visit and the first visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"29.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":57,"n":101},"commonTop":["Asthenia","Anaemia","Neutropenia","Dyspnoea","Constipation"]}}}